- New York’s life sciences vacancy rate rose 70 basis points in the second quarter of 2026 to 32.5%, even as available space held steady.
- Venture capital funding reached $1.9 billion in the quarter, up from $800 million a year earlier, while NIH funding tracked toward its usual $3 billion annual pace.
- Strong capital flows and AI-driven deals point to long-term demand, but excess lab supply and public-sector cutbacks could slow the recovery.
New York life sciences real estate is caught between a vacancy problem and a funding surge, according to a Savills second-quarter report covered by GlobeSt. Vacancy rose to 32.5% in Q2 2026, while venture capital funding more than doubled from a year earlier.
Get Smarter About What Matters in New York
Subscribe to our free newsletter covering the biggest commercial real estate stories across the five boroughs — delivered in just 5 minutes.
Space Isn’t Moving
Available lab space in the market has held flat at 700,000 square feet since June 2025. Even so, vacancy jumped 70 basis points from the prior quarter to reach 32.5%, according to Savills.
The Details
Life science venture funding in New York hit $1.9 billion in the second quarter, up from $800 million in Q2 2025. NIH funding reached about $1.5 billion in the first half, keeping the market on track for the roughly $3 billion annual total it has logged each year since 2022.
NYU BioLabs signed the quarter’s largest lease, taking 46,000 square feet in Long Island City. Syneos Health and The Jackson Laboratory followed with deals of 42,741 and 41,000 square feet, respectively.
AI Enters the Lab
Savills highlighted Anthropic’s $400 million acquisition of Coefficient Bio as evidence of continued momentum in AI-driven life sciences. The deal suggests tech capital is increasingly treating biotech as a growth market.
New York’s split picture echoes national trends, where life sciences rents have softened as supply outpaces tenant demand.
Why It Matters
For landlords, the gap between capital raised and space leased is the key tension. Funding typically precedes hiring and expansion, so a doubling in VC dollars could eventually translate into lab demand, but vacancy above 30% leaves little pricing power in the near term.
Other emerging markets are chasing the same tenants, with Dallas-Fort Worth drawing startups and investors of its own.
What’s Next
Savills flagged a potential headwind: the New York City Economic Development Corp. has cut 75% of its life science workforce, raising questions about public support for the sector’s growth. Whether the funding surge turns into leasing will be the metric to watch in coming quarters.
